Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 1
1989 1
1990 2
1991 4
1992 1
1996 1
1997 2
1998 6
2000 3
2001 1
2003 3
2004 1
2005 1
2006 3
2007 2
2008 4
2009 7
2010 8
2011 5
2012 4
2013 1
2014 3
2017 2
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Quintás-Cardama A, et al. Among authors: scherle pa. Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3. Blood. 2010. PMID: 20130243 Free PMC article.
Development of c-MET pathway inhibitors.
Liu X, Newton RC, Scherle PA. Liu X, et al. Among authors: scherle pa. Expert Opin Investig Drugs. 2011 Sep;20(9):1225-41. doi: 10.1517/13543784.2011.600687. Epub 2011 Jul 11. Expert Opin Investig Drugs. 2011. PMID: 21740293 Review.
ADAM proteases, ErbB pathways and cancer.
Zhou BB, Fridman JS, Liu X, Friedman SM, Newton RC, Scherle PA. Zhou BB, et al. Among authors: scherle pa. Expert Opin Investig Drugs. 2005 Jun;14(6):591-606. doi: 10.1517/13543784.14.6.591. Expert Opin Investig Drugs. 2005. PMID: 16004590 Review.
Targeting the c-MET signaling pathway for cancer therapy.
Liu X, Yao W, Newton RC, Scherle PA. Liu X, et al. Among authors: scherle pa. Expert Opin Investig Drugs. 2008 Jul;17(7):997-1011. doi: 10.1517/13543784.17.7.997. Expert Opin Investig Drugs. 2008. PMID: 18549337 Review.
ADAM-mediated amphiregulin shedding and EGFR transactivation.
Kasina S, Scherle PA, Hall CL, Macoska JA. Kasina S, et al. Among authors: scherle pa. Cell Prolif. 2009 Dec;42(6):799-812. doi: 10.1111/j.1365-2184.2009.00645.x. Epub 2009 Sep 7. Cell Prolif. 2009. PMID: 19735466 Free PMC article.
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.
Yue EW, Sparks R, Polam P, Modi D, Douty B, Wayland B, Glass B, Takvorian A, Glenn J, Zhu W, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Emm T, Scherle PA, Metcalf B, Combs AP. Yue EW, et al. Among authors: scherle pa. ACS Med Chem Lett. 2017 Mar 6;8(5):486-491. doi: 10.1021/acsmedchemlett.6b00391. eCollection 2017 May 11. ACS Med Chem Lett. 2017. PMID: 28523098 Free PMC article.
65 results